



## Press Release

### Piramal Enterprises announces Q2FY2014 results

**Total Operating Income for Q2FY2014 up by 31.9% to ₹ 1,138.9 Crores,  
Operating Profit was higher at ₹ 159.9 Crores while net loss was ₹ 32.2 Crores**

**Mumbai, October 23, 2013:** Piramal Enterprises Limited (formerly Piramal Healthcare Limited) ('PEL', NSE: PEL, BSE: 500302) today announced results for Q2FY2014.

For the quarter ended September 30, 2013, the Total Operating Income grew by 31.9% to ₹ 1,138.9 Crores against ₹ 863.5 Crores in Q2FY2013. Operating Profit (OPBITDA) for the quarter was ₹ 159.9 Crores as compared with ₹ 73.7 Crores during the same period last year. Net loss for the quarter was ₹ 32.2 Crores as compared with a net loss of ₹ 92.0 Crores during Q2FY2013.

Revenue from Pharmaceutical Businesses for Q2FY2014 grew by 21.2% over Q2FY2013 to ₹ 734.4 Crores. Revenue from Financial Services (including Investment Income) for the quarter grew by 117.7% over Q2FY2013 to ₹ 183.5 Crores. Revenue from Information Management business for the quarter ended September 30, 2013 grew to ₹ 221.0 Cr; a growth of 28.0% over the same period last year.

#### **H1FY2014 performance:**

Total Operating Income for H1FY2014 was up by 31.0% to ₹ 2,109.1 Crores. The Operating Profit for the half year was higher at ₹ 306.0 Crores against ₹ 151.7 Crores in H1FY2013. Net loss for H1FY2014 was ₹ 178.9 Crores as against a net loss of ₹ 87.9 Crores during the same period last year. The Interest Expenses for the first half of FY2014 was ₹ 549.8 Crores as against ₹ 209.8 Crores in H1FY2013, as the company raised funds to invest in its NBFC operations, shares of Shriram Transport Finance Company and other structured transactions.

For H1FY2014, revenue from Pharmaceutical Businesses was ₹ 1,347.6 Crores as against ₹ 1,221.3 Crores for H1FY2013; a growth of 10.3%. Pharmaceutical businesses represent ~64% of overall revenue for the company. Revenue from Financial Services, representing ~17% of overall revenue, grew by 123.4% to ₹ 354.6 Crores for the half year ending September 30, 2013 as compared with ₹ 158.7 Crores for the same period last year. Revenue from Information Management business, representing ~19% of overall revenue, was ₹ 406.9 Crores for H1FY2014 as against ₹ 230.3 Crores for H1FY2013. H1FY2013 results included the financial results of DRG only for four months as DRG was acquired in June 2012.

For further information on the financials, please visit our website: [www.piramal.com](http://www.piramal.com)

\*\*\*\*\*

## **Note to the Editors:**

### **About the Piramal Group**

The Piramal Group, led by Ajay G. Piramal is one of India's foremost business conglomerates. Driven by the core values of Knowledge Action Care, the Piramal Group has interests in a myriad of industries that encompass healthcare, drug discovery & research, diagnostics, glass, real estate and financial services. The Piramal Group steadfastly pursues inclusive growth while adhering to ethical and value driven practices. The Group's turnover exceeded \$ 1 billion in FY2013.

### **About Piramal Enterprises Ltd.**

Piramal Enterprises is one of India's largest diversified companies, with a presence in pharmaceutical, financial services and information management sectors. Piramal Enterprises had consolidated revenues of over \$ 650 million in FY2013. In the pharmaceutical space, PEL is one of leading custom manufacturing player globally, has presence in the global critical care segment with a portfolio of inhalation and injectible anesthetics and its OTC business is ranked no. 7 in India. PEL is also engaged in drug discovery & research and has strong pipeline of development products. In the financial services space, PEL has a real estate focused PE fund – Indiareit and a NBFC that is focused on lending to real estate, education & infrastructure sector. PEL's information management business, Decision Resources Group is a leading provider of information based services to the healthcare industry.

#### **For investor enquiries, please contact:**

Jatin Lal / Aishwarya Sitharam,  
Investor Relations Team,  
Piramal Enterprises Limited  
Tel: +91 (0) 22 3046 6582 / 6446  
[investor.relations@piramal.com](mailto:investor.relations@piramal.com)

#### **For media enquiries, please contact:**

<b>PIRAMAL ENTERPRISES LIMITED</b> Akansha Pradhan / Riddhi Goradia Corporate Communications, Piramal Group Contact: +91 22 3351 4082 / 4083 <a href="mailto:akansha.pradhan@piramal.com">akansha.pradhan@piramal.com</a> <a href="mailto:riddhi.goradia@piramal.com">riddhi.goradia@piramal.com</a>	<b>PUBLIC RELATIONS AGENCY</b> Janhavi Bellare / Rakesh Reddy Hanmer MSL Tel: +91-22-6633 5969 Mobile: +91 9322854508 / +91 9321735515 <a href="mailto:Janhavi.bellare@hanmermsl.com">Janhavi.bellare@hanmermsl.com</a> <a href="mailto:rakesh.reddy@hanmermsl.com">rakesh.reddy@hanmermsl.com</a>
--	--